Vimarsana
Biggest News Aggregation in the World

Page 22 - Oche News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oche Today - Breaking & Trending Today

Chemed Co. (NYSE:CHE) Shares Bought by Handelsbanken Fonder AB - Vimarsana News

Chemed Co. (NYSE:CHE) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 20.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 2,372 shares of the company’s stock after acquiring an additional 400 shares during the period. Handelsbanken Fonder AB’s holdings in Chemed were […]

Teacher Education Institute programmes cleared by NCHE to commence next year - Vimarsana News

Teacher Education Institute programmes cleared by NCHE to commence next year

Education

Firsthand look at 43-foot-long golden spike - Vimarsana News

Firsthand look at 43-foot-long golden spike

Last weekend I was able to see what might be one of the nation’s finest monuments on its way to its final destination in Brigham City, Utah. My daughter, Natalie,

Vivek Ramaswamy's Biotech Firm Flipped $15 Million Asset Into $5 Billion - Vimarsana News

Vivek Ramaswamy's Biotech Firm Flipped $15 Million Asset Into $5 Billion

Pfizer will still benefit from the 25% stake it retained as well as full rights to the drug outside the US and Japan.

Roche buys Telavant Holdings for $7.1 billion - Vimarsana News

Roche buys Telavant Holdings for $7.1 billion

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage tria...

Source: yahoo.com